With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

Fer­Gene was born ready. By the time Fer­ring spun out the biotech with a gene ther­a­py li­censed from FKD Ther­a­pies Oy and $400 mil­lion in cash from Black­stone, they had se­cured a pri­or­i­ty re­view on their BLA and point­ed to an im­mi­nent date for the piv­otal Phase III read­out in blad­der can­cer.

The date came yes­ter­day, and Fer­Gene said its ex­per­i­men­tal drug did not dis­ap­point.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER